~~UNITED~~SECURITIES ~~STATES~~AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

~~(Mark~~ [X] ~~One~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017

x[ ~~QUARTERLY~~] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ~~1934~~1934For the transition period from _________ to ________

~~For~~Commission ~~the~~File ~~Quarter~~Number: ~~Ended September 30, 2016~~000-52886

oEASTGATE ~~TRANSITION~~BIOTECH ~~REPORT PURSUANT TO SECTION 13 OR 15~~CORP.(d)Exact OFname ~~THE~~of ~~SECURITIES~~registrant ~~EXCHANGE~~as ~~ACT~~specified OFin ~~1934~~its charter)

For the transition period from _______ to _______

Nevada

87-0639378

(State or other jurisdiction of incorporation organization)

(I.R.S. Employer Identification No.)

~~Commission~~2203-65 ~~File~~Harbour ~~Number~~Square, ~~000-52886~~Toronto, Ontario, Canada M5J 2L4(Address of principal executive offices) (Zip Code)

~~EASTGATE~~Registrant’s ~~BIOTECH~~Telephone ~~CORP.~~Number, ~~(Exact~~Including ~~name~~Area ~~of registrant as specified in its charter)~~Code: 647-692-0652

Nevada		87-0639378
(State or other jurisdiction of incorporation or organization)		(I.R.S. EmployerIdentification No.)

_______________________________________________________________
(Former name, former address and former fiscal year, if changed since last report)

~~2203-65~~Indicate ~~Harbour~~by ~~Square|Toronto~~check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), ~~Ontario|Canada~~and ~~M5J~~(2) ~~2L4~~has been subject to such filing requirements for the past 90 days. Yes [ ] No [ X ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (~~Address~~§232.405 of ~~principal~~this ~~executive~~chapter) ~~offices~~during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ X ] No [ ]

~~(647)~~Indicate ~~692~~by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-~~0652~~accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

~~(Registrant's~~Large ~~telephone~~accelerated ~~number,~~filer ~~including~~[ ~~area~~] ~~code)~~Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [ X ] Emerging growth company [ ]

Indicate by check mark whether the registrant ~~(1)~~is ~~has~~a ~~filed~~shell ~~all~~company ~~reports~~(as ~~required~~defined toin beRule ~~filed~~12b-2 ~~by Section 13 or 15(d)~~ of the ~~Securities~~ Exchange Act ~~of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports~~)~~, and (2) has been subject to such filing requirements for the past 90 days~~. ~~Yes o No x~~

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 1 Yes x[ ] No o[X]

Indicate bythe ~~check~~number ~~mark~~of ~~whether~~shares ~~the~~outstanding ~~registrant~~of iseach aof ~~large~~the ~~accelerated~~issuer’s ~~filer,~~classes anof ~~accelerated~~common ~~filer~~stock, aas ~~non-accelerated~~of ~~filer,~~the orlatest apracticable ~~smaller~~date: ~~reporting~~974,305,508 ~~company~~as August 16, 2018.

Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company x (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.

Class		Outstanding as of March 15, 2017
Common Stock, $0.00001 par value		306,822,175

TABLE OF CONTENTS

Heading		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements		3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		10
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		15
Item 4.	Controls and Procedures		15
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings		16
Item 1A.	Risk Factors		16
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		16
Item 3.	Defaults Upon Senior Securities		16
Item 4.	Mine Safety Disclosures		16
Item 5.	Other Information		16
Item 6.	Exhibits		17
	Signatures		18

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying unaudited balance sheet of Eastgate Biotech Corp. at September 30, 2016, related unaudited statements of operations and cash flows for the periods ended September 30, 2016 and 2015 have been prepared by management in conformity with United States generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2015 audited financial statements. Operating results for the period ended September 30, 2016, are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2016 or any other subsequent period.

3 Table of Contents

EASTGATE BIOTECH CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS


INDEX
			Page
PART I.	FINANCIAL INFORMATION
	ITEM 1	Financial Statements
		Consolidated balance sheets as of March 31, 2017, and December 31, 2016 (unaudited)	F-1
		Consolidated statements of operations for the three months ended March 31, 2017 and 2016 (unaudited)	F-2
		Consolidated statements of cash flows for the three months ended March 31, 2017 and 2016 (unaudited)	F-3
		Notes to consolidated financial statements (unaudited)	F-4 to F-9
	ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13-18
	ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	18
	ITEM 4.	Controls and Procedures	18-19
PART II.	OTHER INFORMATION
	ITEM 1.	Legal Proceedings	19
	ITEM 1A.	Risk Factors	19
	ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
	ITEM 3.	Defaults Upon Senior Securities	18
	ITEM 4.	Mine Safety Disclosures	18
	ITEM 5.	Other Information	18
	ITEM 6.	Exhibits	18
	SIGNATURES		19

	September 30			December 31,
	2016			2015
	(Unaudited)
ASSETS
Current
Cash	$	-		$	19,241
Deposits		251,160			14,595
Sales tax recoverable		98,283			79,681
Total current assets		349,443			113,517
Other assets
Property & Equipment, net		143,746			184,402
Total other assets		493,189			297,919
Total assets	$	493,189		$	297,919
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Bank indebtedness		935
Accounts payable and accrued liabilities	$	367,204		$	361,094
Deferred revenue		-			23,847
Accrued liabilities related party		1,949,737			732,125
Deferred rent		1,026			2,064
Capital lease obligation		10,102			8,130
Accrued interest - related parties		395,282			292,769
Notes payable - related parties		1,506,672			1,308,585
Total current liabilities		4,230,958			2,728,614
Long term liabilities
Capital lease obligation long term		41,391			50,386
Total Liabilities		4,272,349			2,779,000
Stockholders' equity (deficit)
Authorized:
Preferred stock:50,000,000 shares authorized at $0.00001 par value no shares issued at September 30, 2016 and December 31, 2015		-			-
Common stock: 450,000,000 shares authorized at $0.00001 par value 306,822,175 and 282,872,175 shares issued and outstanding at September 30, 2016 and December 31, 2015 respectively		3,069			2,829
Additional paid-in capital		9,891,004			9,137,764
Accumulated other comprehensive income		23,246			31,846
Deficit accumulated		(13,696,479	)		(11,653,520	)
Total stockholders' equity (deficit)		(3,779,160	)		(2,481,081	)
Total liabilities and stockholders' equity (deficit)	$	493,189		$	297,919

~~The~~PART ~~accompanying~~1 ~~notes~~- ~~are~~FINANCIAL ~~an integral part of these condensed consolidated financial statements.~~INFORMATION

4Item ~~Table~~1. ofFinancial ~~Contents~~Statements.

~~EASTGATE~~Forward ~~BIOTECH~~Looking ~~CORP.~~Statements

~~CONDENSED~~This ~~CONSOLIDATED~~quarterly ~~STATEMENTS~~report OFcontains ~~OPERATIONS~~forward-looking ~~AND~~statements. ~~COMPREHENSIVE~~These ~~LOSS~~statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks include, by way of example and not in limitation:

~~(Unaudited)~~·

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2016			2015			2016			2015
REVENUES	$	1,689		$	73,179		$	93,525		$	131,722
Cost of goods sold		-			11,059			13,963			19,489
Gross (loss) profit		1,689			62,120			79,562			112,233
OPERATING EXPENSES
Professional fees		19,886			26,757		$	24,191		$	123,960
Research & development		115,518			257,380			367,070			951,358
General and administrative		435,994			464,756			1,287,603			1,974,458
Marketing and selling		107,454			119,594			327,144			439,330
		678,852			868,487			2,006,008			3,489,106
LOSS FROM OPERATIONS		(677,163	)		(806,367	)		(1,926,446	)		(3,376,873	)
Other items
Interest expense		(39,778	)		(29,449	)		(116,516	)		(78,802	)
Total other items		(39,778	)		(29,449	)		(116,516	)		(78,802	)
LOSS BEFORE INCOME TAXES		(716,941	)		(835,816	)		(2,042,962	)		(3,455,675	)
NET LOSS	$	(716,941	)	$	(835,816	)	$	(2,042,962	)	$	(3,455,675	)
BASIC AND DILUTED LOSS PER SHARE	$	(0.002	)	$	(0.00	)	$	(0.007	)	$	(0.02	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		306,732,501			217,302,267			303,779,292			161,087,899
COMPREHENSIVE LOSS
A summary of the components of other comprehensive loss for the periods ended is as follows:
Net Loss		(716,941	)		(835,816	)		(2,042,962	)		(3,455,675	)
Other Comprehensive Loss - foreign currency translation		3,213			15,107			(8,600	)		9,794
Comprehensive Loss	$	(713,728	)	$	(820,709	)	$	(2,051,562	)	$	(3,445,881	)

the uncertainty that we will not be able to successfully execute our business plan;

~~The accompanying notes are an integral part of these condensed consolidated financial statements.~~·

5risks ~~Table~~related to the large number of ~~Contents~~established and well-financed entities that are actively seeking suitable business opportunities;

~~EASTGATE BIOTECH CORP.~~·

~~CONDENSED~~risks ~~CONSOLIDATED~~related ~~STATEMENTS~~to OFthe ~~CASH~~failure ~~FLOWS~~to successfully manage or achieve growth of a new business opportunity; and

~~(Unaudited)~~·

		For the Nine Months Ended
		September 30,			September 30,
		2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	(2)	$	(2,042,962	)	$	(3,455,675	)
Adjustments to reconcile net loss to net cash used by operating activities:
Expenses paid on the Company's behalf by a related party	8		(3,145	)
Common stock issued for services	1		753,480			1,413,109
Depreciation	3		40,656			30,693
Stock options issued			(6	)		291,427
Changes in operating assets and liabilities:
Accrued interest	-		102,513			78,802
Prepaid asset	(2)		(236,565	)		(55,333	)
Accounts payable	-5		(7,403	)		67,498
Accounts Receivable			-			(38,392	)
Accrued liabilities related party	2		1,212,628			1,150,291
Sales tax recoverable	(6)		(14,124	)		(31,283	)
Deferred rent			(1,147	)		(1,206	)
Deferred revenue			(25,048	)
Cash flows used in operating activities	(1)		(221,124	)		(550,069	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(3)		-			-
Cash flows used in investing activities	(3)		-			-
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of capital lease obligation	-		(7,023	)		(4,130	)
Proceeds from notes payable related party	8		201,233			280,624
Payments on notes payable related party	(5)		-			(5,536	)
Common stock issued for cash	-		-			5,000
Cash Overdraft						6,345
Cash flows provided by financing activities	3		194,210			282,303
NET INCREASE (DECREASE) IN CASH	(1)		(26,913	)		(267,766	)
Effect of foreign currency translation adjustments			7,672			(18,715	)
Cash, beginning of the period			19,241			286,481
Cash, end of the period		$	-		$	-
Supplemental disclosures of cash flow information:
Cash paid for income taxes		$	-		$	-
Cash paid for interest		$	10,429		$	1,261
Non Cash Financing activities:
Common stock issued to convert liabilities		$	-		$	1,317,330
Common stock issued - subscription payable		$	-		$	-
Common stock issued for placement fees		$	-			85,401
Employee Advance repaid for reduction of Notes payable Related Party			-		$	3,359

other risks and uncertainties related to our business strategy.

~~The~~This ~~accompanying~~list ~~notes~~is ~~are~~not an ~~integral~~exhaustive ~~part~~list of ~~these~~the ~~condensed~~factors ~~consolidated~~that ~~financial~~may affect any of our forward-looking statements. These and other factors should be considered carefully, and readers should not place undue reliance on our forward-looking statements.

6Forward ~~Table~~looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made, and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of ~~Contents~~activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

~~EASTGATE~~Our ~~BIOTECH~~unaudited ~~CORP~~consolidated financial statements are stated in United States dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended March 31, 2017, are not necessarily indicative of the results that can be expected for the full year.

~~Notes~~As toused ~~Condensed~~in ~~Financial~~this ~~Statements~~quarterly report, the terms “we”, “us”, “our”, “our company” and “Eastgate” mean Eastgate Biotech, Corp., a Nevada corporation, and its’ wholly-owned subsidiary, Eastgate Pharmaceuticals, Inc., a Canadian corporation.

~~September 30, 2016 and December 31, 2015~~3

NOTE 1 - CONDENSED FINANCIAL STATEMENTS


EASTGATE BIOTECH CORP. & SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(Unaudited)
	March 31, 2017	December 31, 2016
ASSETS
Current assets:
Cash	$ 9,348	$ -
Total current assets	9,348	-

Fixed and intangible assets:
Fixed and intangible assets, net	-	-

Other assets:
Total other assets	-	-

Total assets	$ 9,348	$ -

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Bank overdraft	$ -	$ 32,787
Accounts payable and accrued expenses	423,705	279,688
Accrued interest	18,000	-
Accrued liabilities related party	2,100,055	2,095,891
Deferred revenue	93,326	92,516
Deferred rent	633	627
Capital lease obligation	10,368	10,368
Notes payable	70,403	-
Accrued interest - related party	472,836	432,943
Notes payable - related party	1,704,785	1,633,222
Total current liabilities	4,894,110	4,578,042

Long-term liabilities:
Capital lease obligation	40,024	40,024
Total long-term liabilities	40,024	40,024

Total liabilities	4,934,134	4,618,066

Commitments and contingencies	-	-

Stockholders' deficit
Preferred stock - $0.00001 par value; authorized - 50,000,000 shares; issued and outstanding -0- and -0-, at March 31, 2017 and December 31, 2017 respectively	-	-
Common Stock - $0.00001 par value; 450,000,000 shares authorize; issued and outstanding 322,872,175 and 309,522,175 shares, respectively	3,262	3,096
Additional paid-in capital	10,626,491	9,970,127
Other comprehensive income	28,563	39,702
Accumulated deficit	(15,583,102)	(14,630,991)
Total stockholders' deficit	(4,924,786)	(4,618,066)

Total liabilities and stockholders' deficit	$ 9,348	$ -

See accompanying notes to the financial statements
F-1

The accompanying financial statements have been prepared by the Eastgate Biotech Corp without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2016, and for all periods presented herein have been made.


EASTGATE BIOTECH CORP. & SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)

	For the three months ended
	March 31, 2017	March 31, 2016


Revenues	$ -	$ -

Cost of Sales
Cost of goods sold	-	-

Gross profit	-	-

Operating expenses:
Professional fees	42,667	2,636
Research and development	175,990	138,641
General and administrative	635,941	1,032,220
Marketing and selling	60,090	70,281
Total operating expenses	914,688	1,243,778

Loss from operations	(914,688)	(1,243,778)

Other (Expense):
Interest expense	(37,424)	(35,336)
Loss from Impairment of Assets	-	(184,402)
Total other (expense)	(37,424)	(219,738)

Net loss applicable to common stock holders	$ (952,111)	$ (1,463,516)

Per share data
Net loss per share - basic and diluted	$ (0.00)	$ (0.01)


Weighted average number of shares outstanding - basic and diluted	318,069,953	298,300,747

Net Loss	(952,111)	(1,463,516)
Other Comprehensive Income (Loss) - foreign currency translation	11,139	(15,623)
Comprehensive Loss	(940,972)	(1,479,139)

See accompanying notes to the financial statements
F-2

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2015 audited financial statements. The results of operations for the periods ended September 30, 2016 and 2015 are not necessarily indicative of the operating results for the full years.


EASTGATE BIOTECH CORP. & SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	For the three months ended
	March 31, 2017	March 31, 2016
		(Restated)
Cash flows from operating activities:
Net loss	$ (952,111)	$ (1,463,516)
Adjustments to reconcile net loss to net cash
used in operating activities:
Expenses paid on the Company's behalf by related party	-	(611)
Common stock issued for services	191,030	753,480
Stock based compensation	465,500	-
Loss from impairment of assets	-	184,402
Changes in operating asset and liability account balances:
Accrued liabilities related party	4,164	398,021
Reserve for recoverable taxes	-	(7,382)
Deferred rent	6	(368)
Deferred revenue	810	1,085
Prepaid asset	-	14,595
Accrued interest	57,893	31,918
Accounts payable and accrued expenses	111,229	(15,126)
Total adjustments	830,632	1,360,013

Net cash used in operating activities	(121,479)	(103,503)

Cash flows from investing activities
Net cash used in investing activities	-	-

Cash flows from financing activities:
Payment of capital lease obligation	-	(1,973)
Proceeds from related party notes payable	71,563	94,077
Proceeds from notes payable	70,403	-
Net cash provided by financing activities	141,966	92,104

Net increase (decrease) in cash	20,487	(11,399)

Effect of foreign currency translation adjustments	(11,139)	2,972

Cash at beginning of period	-	19,241

Cash at end of period	$ 9,348	$ 10,814

Supplemental Schedule of Cash Flow Information:
Cash paid for interest	$ -	$ 3,424
Cash paid for income taxes	$ -	$ -

See accompanying notes to the financial statements
F-3

~~NOTE~~Eastgate 2Biotech -Corp. ~~GOING~~and ~~CONCERN~~Subsidiary

~~The~~Notes ~~accompanying~~to ~~financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of~~ the ~~Company~~Unaudited asConsolidated aFinancial going concern. However, the Company has accumulated deficit of $13,696,479 as of September 30, 2016. The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time, raising substantial doubt about its ability to continue as a going concern.Statements

~~Management~~ For ~~anticipates that~~ the ~~Company~~three ~~will~~months beended ~~dependent,~~March ~~for the near future~~31, on2017 additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and ~~continue as a going concern.~~2016

~~NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES~~1.

~~Principles~~Basis of ~~Consolidation~~Presentation

~~The~~Interim ~~consolidated~~Unaudited ~~financial~~Consolidated ~~statements~~Financial ~~include the accounts of Eastgate Biotech Corp. and its wholly-owned subsidiary Eastgate Pharmaceuticals Inc. All intercompany accounts and transactions have been eliminated in consolidation.~~Statements

~~Use~~The unaudited interim consolidated financial statements of ~~Estimates~~Eastgate Biotech Corporation (the “Company,” “Eastgate,” “we,” “our” or “us”) as of March 31, 2017 and for the three-month period ended March 31, 2017 and 2016 contained in this Quarterly Report (collectively, the “Unaudited Interim Consolidated Financial Statements”) were prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for all periods presented. The results of operations for the three-month period ended March 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year.

The ~~preparation~~accompanying ofUnaudited ~~financial~~Interim ~~statements~~Consolidated Financial Statements have been prepared in ~~conformity~~accordance with ~~accounting~~the ~~principles~~regulations ~~generally~~for ~~accepted~~interim infinancial information of the ~~United~~Securities ~~States~~and ofExchange ~~America~~Commission ~~requires~~(the ~~management~~“SEC”). toAccordingly, ~~make~~they ~~estimates~~do ~~and~~not ~~assumptions~~include ~~that~~all ~~affect~~of the ~~reported~~disclosures ~~amounts~~required ofby ~~assets~~U.S. ~~and~~GAAP ~~liabilities~~for atcomplete financial statements. In the ~~date~~opinion of management, the unaudited accompanying statements of financial condition and related interim statements of operations, cash flows, and ~~the~~stockholders’ ~~reported~~deficit ~~amounts~~include all adjustments (which consist only of ~~revenue~~normal and ~~expenses~~recurring ~~during~~adjustments) ~~the~~considered ~~reporting~~necessary ~~period~~for a fair presentation in conformity with U.S. ~~Actual~~GAAP. ~~results~~These ~~could~~Unaudited ~~differ~~Interim ~~from~~Consolidated ~~those~~Financial ~~estimates~~Statements should be read in conjunction with our consolidated financial statements as of and for the year ended December 31, 2016.

~~Cash and Cash Equivalents~~2.

~~For~~Organization ~~purposes~~and ofNature ~~the statement~~ of cash flows, the Company considers all highly liquid instruments purchased with a maturity of six months or less to be cash equivalents to the extent the funds are not being held for investment purposes.Operations

~~7 Table of Contents~~Organization

~~Revenue~~Eastgate ~~Recognition~~Biotech Corp. (The Company) was organized on September 8, 1999, under the laws of the State of

~~The Company recognizes revenue when it is realized or realizable and earned~~Nevada. We consider revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collection is reasonably assured.

~~Research~~During the year ended December 31, 2012 the Company acquired Eastgate Pharmaceuticals Inc. (“EPI”), as a wholly-owned subsidiary of the Company, from our CEO, Anna Gluskin, its sole shareholder, officer, and ~~Development~~director. EPI ~~Costs~~is a Province of Ontario, Canada corporation.

~~The~~Nature ~~Company expenses research and development costs to operations as incurred. Research and development expenses are comprised~~ of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.Business

~~Foreign~~The ~~Currency~~Company ~~Translation~~is engaged in the research and development of drug delivery innovations, development of improved and novel formulations, and forms of alternative dosage delivery of existing biologically active molecules.

~~Foreign~~We ~~denominated~~are ~~assets~~primarily ~~and~~engaged ~~liabilities~~in the development of ~~the~~novel ~~Company~~formulations ~~are~~of ~~translated~~natural ~~into~~compounds Uand pharmaceutical products.S. ~~dollars~~We atintend ~~the~~to ~~prevailing~~accomplish ~~exchange~~this ~~rates~~by indeveloping ~~effect~~our atproprietary ~~the~~self-emulsifying ~~end~~drug ofdelivery ~~the~~systems, ~~reporting~~predominantly ~~period~~forming Nano-emulsions. ~~Income~~Although ~~statement~~we ~~accounts~~have ~~are~~not ~~translated~~finalized atany apharmaceuticals ~~weighted~~products ~~average~~and ofare ~~exchange~~in ~~rates~~the ~~which~~early ~~were~~stages inof ~~effect~~research, ~~during~~our ~~the~~goal ~~period.~~is ~~Translation~~to ~~adjustments~~be ~~that~~able ~~arise~~to ~~from~~develop ~~translating~~patentable ~~the~~and ~~foreign~~Trade ~~subsidiary's~~Secret ~~financial~~formulations ~~statements~~of ~~from~~pharmaceutical, ~~local~~nutraceutical ~~currency~~dietary tosupplements Uand consumer health products.S. ~~currency~~We ~~are~~recently ~~recorded~~started inmarketing ~~the~~and ~~other~~distribution ~~comprehensive~~and ~~loss~~have ~~component~~limited sales for some of ~~stockholders'~~our ~~equity~~nutraceuticals products.

~~Recent Accounting Pronouncements~~F-4

InSome ~~June~~of ~~2014,~~our ~~the~~proposed ~~Financial~~products ~~Accounting~~under ~~Standards~~development ~~Board~~are ~~issued~~based ~~Accounting~~on ~~Standards~~existing ~~Update~~natural Nocompounds. ~~2014-10,~~Many ~~which~~of ~~eliminated~~these ~~certain~~proposed ~~financial~~products ~~reporting~~are ~~requirements~~made of ~~companies~~essential ~~previously~~oils ~~identified~~and asplant ~~"Development~~extracts. ~~Stage~~Our ~~Entities"~~proposed ~~(Topic~~products ~~915).~~comprise ~~The~~excipients ~~amendments~~listed in ~~this~~the ~~ASU~~FDA ~~simplify~~“Inactive ~~accounting~~Ingredients ~~guidance~~Guide” bythat ~~removing~~we ~~all~~believe ~~incremental~~are ~~financial~~safe ~~reporting~~and ~~requirements~~approved for ~~development~~human ~~stage entities~~consumption. ~~The~~Additionally, ~~amendments~~we ~~also~~believe ~~reduce~~that ~~data~~these ~~maintenance~~proposed ~~and,~~products ~~for~~can ~~those~~be ~~entities~~manufactured ~~subject~~using tocommon ~~audit,~~equipment. ~~audit~~We ~~costs~~anticipate bythat ~~eliminating~~we ~~the~~will ~~requirement~~be ~~for~~able ~~development stage entities~~ to ~~present~~apply ~~inception~~self-~~to-date~~emulsifying ~~information~~technologies infor ~~the~~development ~~statements~~ of ~~income,~~a ~~cash~~variety ~~flows, and shareholder equity. Early application~~ of ~~each~~pharmaceuticals ofand ~~the~~natural ~~amendments~~products ~~is permitted~~ for ~~any~~different ~~annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities)~~applications. ~~Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information.~~

~~The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company's financial position or statements~~3.

~~NOTE~~Going ~~4 - RELATED-PARTY TRANSACTIONS~~Concern

~~Notes~~These ~~payable~~accompanying –unaudited ~~related~~consolidated ~~parties~~financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of March 31, 2017, the Company had an accumulated deficit of $15,583,102 and negative working capital of $4,884,762. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities, obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. However, there can be no assurance that these arrangements will be sufficient to fund its ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These accompanying unaudited consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

~~The Company has recorded loans from shareholders, amounts due to shareholders for expenses paid on its behalf by shareholders as Notes payable - related parties on the balance sheet~~4. ~~The amounts comprising Notes payable – related parties bear interest ranging from 5 percent per annum to 10 percent per annum, are unsecured and are due and payable upon demand.~~

~~During~~Basis ~~the nine months ended September 30, 2016 the CEO and companies owned by the CEO as well as a company owned by a related party shareholder have advanced cash to the Company~~ of $201,233, and have had expenses paid by the Company of $3,146 on their behalf. At September 30, 2016 the Company has not repaid any of related party loans. During the year ended December 31, 2015 the CEO and the current President advanced the company cash of $310,825 and were repaid $5,536 of advances made. In addition during this period they paid $2,337 of expenses on behalf of the company and were reimbursed for $5,432 in expenses they previously paid. This accounts for the increase in notes payable related party for the year ended December 31, 2015 of $302,194. As of September 30, 2016 and December 31, 2015, the Company owed $395,281 and $292,798 of accrued interest to related parties, respectively, resulting from interest expense of $102,483 and $109,954, respectively.Presentation

8The ~~Table~~financial statements of ~~Contents~~the Company have been prepared in accordance with US GAAP and are expressed in U.S. dollars. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year end is December 31.

~~NOTE~~ 5 ~~- SALES TAX RECOVERABLE~~.

~~Sales~~Summary ~~tax~~of ~~receivable~~Significant Accounting Policies

The Company recovers sales tax paid, for which returns are filed on annual basis. At September 30, 2016, $98,283 was claimed as recoverable compared to the December 31, 2015 balance of $79,681. Sales tax recoverable is a) Use ~~result~~ of ~~sales tax paid on eligible expenses.~~Estimates

~~NOTE~~The ~~6 -~~preparation ~~STOCKHOLDERS'~~of ~~EQUITY~~unaudited consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Onb) Principles ~~February 1st 2016, the Company issued a total~~ of ~~23,400,000 restricted shares of common stock to various consultants for services rendered at the price of $0.0322 per share.~~Consolidation

OnThe ~~July~~consolidated ~~16,~~financial ~~2016,~~statements ~~550,~~include ~~251~~the ~~warrants~~accounts ~~were~~of ~~exercised by their holders using cashless exercise provision at~~ the ~~price~~Company ofand ~~$0.00001~~its ~~per~~wholly ~~share.~~owned ~~This~~subsidiary ~~resulted~~Eastgate ~~in 550~~Pharmaceuticals,~~000~~ ~~common~~Inc. All ~~shares~~significant ~~being~~inter-company ~~issued~~transactions toare ~~these holders~~eliminated.

~~The following table summarizes the stock options that are issued, outstanding and exercisable~~F-5

			Stock Options Issued & Outstanding
Exercise		Expiration	September 30		December 31
Price		Date	2016		2015
$	0.286	February 12, 2020		10,375,000		10,375,000

c) Cash and Cash Equivalents

AsFor purposes of ~~September~~the ~~30,~~statement ~~2016~~of cash flows, ~~the~~cash ~~Company~~includes ~~had~~demand 41deposits,~~164,901~~ ~~warrants~~saving toaccounts ~~purchase~~and ~~common~~money ~~stock~~market accounts. ~~All~~The ~~outstanding~~Company ~~warrants~~considers ~~have~~all ahighly ~~weighted~~liquid ~~average~~instruments ~~price~~with maturities of ~~$0.07~~three ~~per~~months ~~share~~or ~~and~~less ~~have~~when apurchased ~~weighted~~to ~~average~~be ~~remaining~~cash ~~life of 2~~equivalents.81 ~~years.~~

~~The~~d) Accounts ~~following~~receivable ~~table~~and ~~summarizes~~concentration ~~warrants~~of ~~that~~credit ~~are~~risk ~~issued, outstanding and exercisable~~

			Warrants Issued & Outstanding
Exercise		Expiration	September 30		December 31
Price		Date	2016		2015
$	0.25	March 14, 2019		3,495,000		3,495,000
$	0.25	March 21, 2019		3,480,000		3,480,000
$	0.25	June 6, 2019		2,022,300		2,022,300
$	0.05	October 16, 2019		150,000		150,000
	0.04	December 31, 2019		8,125,000		8,125,000
$	0.04	January 5, 2020		8,146,225		8,146,225
	0.04	August 19, 2020		125,000		125,000
	0.00001	October 6, 2020		15,621,376		16,171,627
				41,164,901		41,715,152

The Company carries no accounts receivable for the periods reported herein. This has currently eliminated the risk of default in the collection of accounts receivable. In addition, our concentration risk, which is evaluated on a quarterly basis is currently, virtually nil.

~~NOTE~~e) Allowance ~~7 -~~for ~~SUBSEQUENT~~doubtful ~~EVENTS~~accounts

InThe ~~accordance~~allowance ~~with~~for ~~ASC~~doubtful ~~855~~accounts ~~Company~~is ~~management~~based ~~reviewed~~on ~~all~~the ~~material~~Company’s ~~events~~assessment ~~through~~of the ~~date~~collectability of ~~this~~customer ~~report~~accounts and ~~determined~~the aging of the accounts receivable. The Company regularly reviews the adequacy of the Company’s allowance for doubtful accounts through identification of specific receivables where it is expected that ~~there~~payments will not be received. The Company also establishes an unallocated reserve that is applied to all amounts that are nonot ~~material~~specifically ~~subsequent~~identified. In ~~events~~determining specific receivables where collections may not have been received, the Company reviews past due receivables and gives consideration to ~~report~~prior ~~except~~collection history and changes in the customer’s overall business condition. The allowance for doubtful accounts reflects the Company’s best estimate as ~~described~~of ~~below:~~the reporting dates.

9At ~~Table~~March 31, 2017 and December 31, 2016, the Company had an allowance for bad debts in the amount of ~~Contents~~$0 and $0, respectively.

~~Item~~f) Basic ~~2. Management's Discussion~~ and ~~Analysis~~Diluted ofNet ~~Financial~~Loss ~~Condition~~per ~~and~~Share ~~Results of Operations~~

~~Results~~The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of ~~Operations~~both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

~~The~~g) Financial ~~following~~Instruments ~~selected comparative financial information has been derived from and should be read in conjunction with the company's financial statements for the nine months ended September 30, 2016 and 2015.~~

	For the Three Months ended						For the Nine Months ended
	September 30						September 30
	2016			2015			2016			2015
Revenues	$	1,689		$	73,179		$	93,525		$	131,722
Cost of sales		-			11,059			13,963			19,489
Gross profit		1,689			62,120			79,562			112,233
Operating Expenses
Professional fees		19,886			26,759			24,191			123,960
Research & development		115,518			257,380			367,070			951,358
General & administrative		435,994			464,756			1,287,603			1,974,458
Marketing and selling		107,454			119,594			327,144			439,330
Total operating expenses		678,852			868,487			2,006,008			3,489,106
Loss from operations		(677,163	)		(806,367	)		(1,926,446	)		(3,376,873	)
Interest income		(39,778	)		(29,449	)		(116,516	)		(78,802	)
Net loss	$	(716,941	)	$	(835,816	)	$	(2,042,962	)	$	(3,455,675	)

Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

	September 30			December 31
	2016			2015
Total assets	$	493,189		$	297,919
Working Capital	$	(3,881,515	)	$	(2,615,097	)

F-6

~~Results~~Level of1 ~~Operations~~applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

~~During~~Level ~~the~~2 ~~three~~applies ~~months~~to ~~ended~~assets ~~September~~or 30liabilities ~~2016~~for ~~company~~which ~~recorded~~there ~~revenue from~~are ~~royalty~~inputs ~~income.~~other ~~During~~than ~~the~~quoted ~~three~~prices ~~months~~that ~~ended~~are ~~September~~observable ~~30, 2016, our net loss was $716,941 compared to a net loss of $835,816~~ for the ~~three~~asset ~~months~~or ~~ended~~liability ~~September~~such ~~30,~~as ~~2015.~~quoted ~~The~~prices ~~decreased loss~~ for ~~2016~~similar ofassets ~~$118,875~~or ~~was~~liabilities ~~primarily~~in ~~due~~active tomarkets; ~~the~~quoted ~~fact~~prices ~~the~~for ~~company~~identical ~~had~~assets ~~reduced~~or ~~G&A~~liabilities ~~expenses~~in bymarkets ~~28,762,~~with ~~the~~insufficient ~~research~~volume ~~and~~or ~~development~~infrequent ~~expenses~~transactions by(less ~~$141,862,~~active ~~professional~~markets); ~~fees~~or ~~decreased~~model-derived ~~respectively~~valuations ~~by $6,871 and marketing & selling expenses decreased by $12,140. These changes~~ in ~~expenditures~~which ~~combined~~significant ~~with~~inputs aare ~~gross~~observable ~~profit~~or oncan ~~royalty~~be ~~revenue~~derived ofprincipally $1from,~~689~~ ~~resulted~~or incorroborated ~~the decreased loss of $118~~by,~~875~~ ~~for~~observable ~~the~~market ~~quarter~~data.

10Level ~~Table~~3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of ~~Contents~~the fair value of the assets or liabilities.

~~During~~The ~~the~~Company ~~nine~~did ~~months~~not ~~ended~~have ~~September~~any ~~30,~~Level ~~2016~~2 ~~company~~or ~~recorded~~Level ~~revenue~~3 ofassets ~~$93,525.~~or ~~During~~liabilities ~~the~~as ~~nine~~of ~~months ended~~ September 30, ~~2016~~2017, ~~our~~with ~~net~~the ~~loss~~exception ~~was $2,042,962 compared to a net loss~~ of ~~$3.455.675~~its ~~for~~notes ~~the nine months ended September 30, 2015~~payable. The ~~decreased~~carrying ~~loss~~amounts ~~for 2016~~ of ~~$1,412,713~~these ~~was~~liabilities ~~due~~at ~~to the fact the company was less active in the nine month period ended~~ September 30, ~~2016~~2017 ~~due~~approximate totheir ~~lack~~respective offair ~~funding.~~value ~~The~~based ~~primary~~on ~~reasons for~~ the ~~decrease~~Company’s ~~were~~incremental ~~decrease~~borrowing in operating expenses including a decrease in professional fees of $99,769, a decrease in R&D expenses of $584,288, a decrease in marketing and selling of $112,186 and a decrease of general and administrative expense of $686,855rate.

~~Sales~~ Cash is considered to be highly liquid and easily tradable as of March 31, 2017 and therefore classified as Level 1 within our fair value hierarchy.

~~This~~In ~~quarter~~addition, weFASB ~~recorded~~ASC ~~revenue~~825-10-25 ofFair $1Value Option,~~689~~ ~~from~~or ~~royalty~~ASC ~~income~~825-10-25, was effective for January 1, 2008. ~~Cost~~ASC of825-10-25 ~~sales~~expands ~~was~~opportunities ~~nil~~to ~~for~~use afair ~~gross~~value ~~profit~~measurements ofin ~~$1,689~~financial ~~compared~~reporting and permits entities to ~~sales~~choose ofto ~~$73,179with~~measure ~~the~~many ~~cost~~financial ofinstruments ~~sales~~and ofcertain ~~$11,059~~other ~~for~~items aat ~~gross~~fair ~~profit~~value. ofThe ~~$62,120~~Company indid not elect the ~~same~~fair ~~quarter~~value ~~ending~~options ~~September~~for 30any ~~2015~~ of its qualifying financial instruments

~~During~~h) Income the nine months ended September 30 2016 we have recorded $93,525 in revenues. Cost of sales was $13,963 for a gross profit of $79,562 compared to revenue of $131,722with the cost of sales of $19,489 for a gross profit of $112,233 for the nine months ended September 30 2015. Taxes

~~Operating~~Potential ~~Expenses~~benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 “Accounting for Income Taxes” as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

~~Professional~~i) ~~fees~~Revenue Recognition

~~During~~The ~~the~~Company ~~third~~recognizes ~~quarter~~revenue ~~ended~~in ~~September~~accordance 30with ASC-605, ~~2016~~“Revenue Recognition,” ~~professional~~which ~~fees~~requires ~~expenses~~that ~~were~~four ~~$19,886,~~basic acriteria ~~decrease~~must be met before revenue can be recognized: (1) persuasive evidence of ~~$6,871~~an ~~from~~arrangement exists; (2) delivery has occurred or title has passed; (3) the ~~third~~selling ~~quarter~~price ofis ~~2015~~fixed ~~professional~~and ~~fees~~determinable; ~~expense~~and of(4) ~~$26,757~~collectability is reasonably assured. ~~The~~Determination ~~decrease~~of ~~can~~criteria be(3) ~~attributed~~and to(4) ~~decrease~~are inbased ~~legal~~on ~~expenses~~management's ~~for~~judgments regarding the ~~quarter~~fixed nature of the selling prices of the products delivered and the collectability of those amounts.

~~During~~Revenues are recognized (a) for larger construction type projects based on the ~~first~~percentage ~~nine~~of ~~months~~completion ~~ended~~method; ~~September~~or ~~30,~~(b) ~~2016,~~for ~~professional~~direct ~~fees~~sales ~~expenses~~of ~~were~~products, ~~$24~~upon shipment,~~191,~~ provided that a ~~decrease~~signed ofpurchase ~~$99,769~~order ~~from~~has ~~the~~been ~~first~~received, ~~nine~~the ~~months~~price ofis ~~2015~~fixed, ~~professional~~title ~~fees~~has ~~expense~~transferred, collection of ~~$123~~resulting receivables is reasonably assured,~~960.~~ ~~The~~and ~~first~~there ~~quarter~~are ofno ~~2015~~remaining ~~included~~significant ~~the~~obligations. ~~costs~~Reserves offor ansales ~~equity~~returns ~~raise;~~and ~~the~~allowances, ~~company~~based ~~did~~on ~~not~~historical ~~have~~levels ~~these~~of ~~expenses~~returns inand ~~the~~discounts, ~~nine~~current ~~months~~economic ~~ended~~trends ~~September~~and 30changes ~~2016~~in customer demand.

~~Research~~Provisions for discounts and ~~development~~rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.

Research and development costs consist of fees paid to consultants for laboratory evaluation of product chemistry and formulation as well as tests and studies to assess the efficacy and potential safety of our products. Also included in research and development are laboratory consumables.F-7

~~During~~j) the third quarter ended September 30, 2016, research and development expenses of $115,518 decreased by $141,862 from $257,380 for the third quarter of 2015. The decrease was a result of the company's lack of funding.Reclassification

~~During~~Certain ~~the~~reclassifications ~~nine~~have ~~months~~been ~~ended~~made ~~September~~to ~~30,~~conform ~~2016,~~the ~~research~~prior ~~and~~period ~~development~~data ~~expenses~~to ~~of $367,070 decreased by $584,288 from $951,358 for~~ the ~~first~~current ~~nine months of 2015~~presentation. ~~The~~These ~~decrease~~reclassifications ~~was~~had ano ~~result~~effect ofon ~~the~~reported ~~company’s~~net ~~lack of funding~~loss.

~~General and administrative~~6.

~~During~~Notes ~~the third quarter of 2016, we incurred general and administrative expenses of $435,994 a decrease of $28,762 from $464,756 for the third quarter of 2015.~~ Payable

~~During~~Notes ~~the~~Payable ~~first~~to ~~nine~~Related ~~months of 2016, we incurred general and administrative expenses of $1,287,603, a decrease of $686,855 from $1,974,458 for the first nine months of 2015.~~ Parties:

11The ~~Table~~Company ofowed ~~Contents~~$2,177,621 and $2,066,165 in notes and accrued interest to an officer and director at March 31, 2017 and December 31, 2016, respectively.

~~Marketing~~During the three months ended March 31, 2017 and ~~selling~~2016, the Company made no repayments of notes or accrued interest.

~~During~~Notes ~~the third quarter ended September 30~~Payable, ~~2016, marketing and selling expenses of $107,454 decreased by $12,140 from $119,594 for the third quarter of 2015. The decrease is a result of the company reduced promotional activities during 2016.~~ others:

~~During~~The ~~the~~company ~~nine~~has ~~months~~notes ~~ended~~due ~~September~~to ~~30,~~unrelated ~~2016,~~parties ~~marketing~~totaling ~~and selling expenses of~~ $~~327~~70,~~144~~403 ~~decreased~~and by $~~112,186~~0 ~~from~~at ~~$439~~March 31,~~330~~ ~~for~~2017 ~~the~~and ~~nine~~December ~~months~~31, ~~ended September 30~~2016, ~~2015~~respectively. The decrease is a result of lack of funding. The company continuing negotiations in various parts of the world for the sale of distribution licenses for the sale of the company’s pharmaceutical and nutraceutical products.

~~Interest~~At ~~expense~~March 31, 2017 and December 31, 2016, the Company has accrued interest of $18,000 and $0, respectively.

~~Interest expense of $39,778 for the third quarter ended September 30, 2016 an increase of $10,329 from $29,449 for the third quarter of 2015~~7. ~~The increase is attributed to an increase in loans from stockholders during the period.~~

~~Interest~~Related ~~expense~~Party of $116,516 for the nine months ended September 30, 2016 an increase of $37,714 from $78,802 for the nine months ended September 30, 2015. The increase is attributed to an increase in loans from stockholders during the period.Transactions

~~Liquidity~~The Company owes accrued compensation totaling $799,270 and ~~Capital~~$733,333 ~~Resources~~to two officers at March 31, 2017 and December 31, 2016, respectively.

AtDuring ~~September~~the ~~30,~~three ~~2016~~months weended ~~had~~March ~~a working capital deficit of $3,881,515 which is an increase of $1,266,418 from the December~~ 31, ~~2015~~2017 ~~deficit~~and ~~balance of $2~~2016,~~615,097.~~ ~~The increase in~~ the ~~deficit~~Company ismade ~~primarily~~repayments ~~a result~~ of ~~the~~accrued ~~loss~~compensation ~~for the nine months~~ of $2,~~042,962~~156 ~~netted~~and ~~by the~~ $~~753~~0,~~480~~ ~~of this loss having been paid by issuing common stock for services~~respectively.

~~Expenses~~As ~~incurred~~of ~~during~~December 31, 2016, ~~have~~$107,069 ~~been~~of ~~paid for by related parties including our current CEO and current President as well as through issuing~~ the ~~company~~Company’s ~~common~~accounts ~~stock.~~payable ~~Because~~are weowed ~~have no cash reserves or generate sufficient revenue, we expect~~ to ~~continue~~two toformerly ~~rely~~related ~~on the stockholders and equity raises to pay expenses until such time as we can generate sufficient cash flows to pay our ongoing operational costs~~parties. ~~There is no assurance that the company will be able to obtain equity raises before the company develops revenue sources with sufficient cash flow to cover expenses.~~

During the nine months ended September 30, 2016 the stockholders contributed a net amount of $198,087, made up of $201,233 advanced in cash less $3,146 of expenses paid by the company on behalf of the related party8. At September 30, 2016 and December 31, 2015, we had bank overdraft of $935 and cash on hand of $19,241, respectively. At September 30, 2016 we had accrued liabilities - related party of $1,949,737, compared to $732,125 at December 31, 2015. The increase represents the accrual of wages to company executive officers during the nine month ended September 30, 2016. At September 30, 2016 we had notes payable - related party of $1,506,672, compared to $1,308,585 at December 31, 2015. The increase represents additional contributions from stockholders during the nine months ended September 30, 2016. Accrued interest – related party at September 30, 2016 was $395,281 compared to $292,769 at December 31, 2015, which reflects the added interest of $102,513 on the related party payable. Accounts payable and accrued liabilities increased by $6,110 from $361,094 at December 31, 2015, to $367,204 at September 30, 2016, primarily a result of the fact the company is in a fund raising situation.

InStockholders’ the opinion of management, inflation has not and will not have a material effect on our operations until such time as we raise funds or successfully complete an acquisition or merger. At that time, management will evaluate the possible effects of inflation related to our business and operations.Equity

~~At September 30, 2016, we had~~ a) stockholders' deficit of $3,779,160 compared to a stockholders' deficit of $2,481,081 at December 31, 2015. The increase in stockholders' deficit is primarily attributed to operating loss offset by the issuance of common stock for service in the first nine months of 2016.

~~12 Table of Contents~~Authorized

AsAuthorized ofcapital ~~March~~stock ~~10,~~consists ~~2017, we had cash on hand~~ of $2,428. We believe that our available cash combined with continued advances from related parties will be sufficient to carry on general corporate functions for the next three months, although we will need to limit cash outlays for research and product development until we can secure additional funds. We are presently investigating possible funding opportunities to arrange for additional funds, although we do not have any definitive agreement or arrangement for such funds. We expect that additional funding to proceed with development of the intellectual property acquired in 2015 will most likely be from the sale of securities or from stockholder loans. We may not be successful in our efforts to obtain equity financing to carry out our business plan and there is doubt regarding our ability to complete our planned development program. We estimate that cash requirements for the next twelve months will be approximately $5,000,000. In the past year, we have relied on advances from related parties for financing our operations. We continue to explore potential funding opportunities, which may be in the form of debt or the sale of equity securities. In the event we are unsuccessful in arranging for outside funding, we will most likely continue to rely on related parties to provide funding, although there are no firm commitments or agreements with any related party to provide funds in the future.:

~~Net~~· ~~Operating~~450,000,000 ~~Loss~~shares of common stock with a par value of $0.00001 per share; and

We have accumulated a net operating loss carryforward of approximately $11,653,520 as of December 31, 2015. This loss carry forward may be offset against future taxable income through the year 2033. The use of these losses to reduce future income taxes will depend on the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. In the event of certain changes in control, there will be an annual limitation on the amount of net operating loss carryforwards that can be used. No tax benefit has been reported in the financial statements for the year ended December 31, 2015 or the nine month period ended September 30, 2016 because it has been fully offset by a valuation reserve. The use of future tax benefit is undeterminable because we presently have no operations.·

~~Recent~~50,000,000 ~~Accounting~~preferred ~~Pronouncements~~shares with a par value of $0.00001 per share

~~In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014~~F-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information.8

~~The~~b) ~~company~~Share ~~has evaluated other recent accounting pronouncements and their adoption has not had nor is expected to have a material impact on the company's financial position or statements.~~Issuances

~~Off-Balance~~During ~~Sheet~~the ~~Arrangements~~period ended March 31, 2017, the Company issued the following common shares:

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.·

~~Plan~~In January 2017, the Company issued 1,000,000 shares of ~~Operation~~common stock at an average price of $0.0318 per share (the share price at the time of issuance) to consultants who are also accredited investors.

Following the closing of a patent acquisition agreement (the "Acquisition Agreement") in 2012, we have become engaged in the development and ultimate formulation of other novel formulations of natural compounds and pharmaceutical products that have limitations in effective use for human consumption. We believe our self-emulsifying drug delivery technology can improve the efficacy of existing products and formulations based on natural or well-established compounds and known biologically active compounds. We intend to conduct our research and development through collaborative programs. We anticipate relying on arrangements with third party drug developers such as contract research organizations and clinical research sites for a significant portion of our product development efforts.·

~~The~~In ~~Acquisition~~February ~~Agreement~~2017, ~~enabled~~the usCompany toissued ~~acquire certain products~~8, ~~formulas~~100,000 ~~processes,~~shares ~~proprietary~~of ~~technology~~common ~~and/or~~stock ~~patents~~at ~~and~~an ~~patent~~average ~~applications~~price ~~related~~of ~~to pharmaceutical, nutraceutical, food supplements and consumer health products~~$0.0399 Weper ~~have~~share ~~not~~(the ~~formulated~~share ~~any~~price ~~final~~at ~~products~~the ortime ~~receive~~of ~~approvals~~issuance) ~~from~~to ~~any~~consultants ~~regulatory~~who ~~agencies~~are oralso ~~generated~~accredited ~~any revenues from product sales~~investors. ~~We have not been profitable since our inception through the current date.~~

~~13 Table of Contents~~·

WeIn ~~expect~~March to2017, ~~incur significant operating losses for~~ the ~~next~~Company ~~several~~issued ~~years~~3,000,000 ~~and~~shares ~~until~~of wecommon ~~are~~stock ~~able~~at toan ~~formulate~~average aprice ~~commercially~~of ~~viable product~~$0.04 Weper ~~also~~share ~~expect~~(the toshare ~~continue~~price toat ~~incur~~the ~~significant~~time ~~operating~~of ~~and~~issuance) ~~capital~~to ~~expenditures~~consultants ~~and~~who ~~anticipate~~are ~~that~~also ~~our~~accredited ~~expenses will increase substantially in the foreseeable future as we:~~investors.

· Continue to undertake formulation of novel products and subsequent preclinical and clinical trials for our product candidates; · Seek regulatory approvals for our product candidates; · Develop, formulate, manufacture and commercialize our products; · Implement additional internal systems and develop new infrastructure; · Acquire or in-license additional products or technologies, or expand the use of our technology; · Maintain, defend and expand the scope of our intellectual property; and · Hire qualified personnel.

~~Future~~In ~~product~~March ~~revenue will depend on our ability to develops~~2017, ~~receive~~the ~~regulatory~~Company ~~approvals~~issued ~~for~~500,000 ~~and~~shares ~~successfully market, our product candidates. In the event that our development efforts result in regulatory approval and successful commercialization~~ of ~~our~~common ~~product~~stock ~~candidates,~~at wean ~~will~~average ~~generate~~price ~~revenue from direct sales~~ of ~~our~~$0.043 ~~products~~per ~~and/or,~~share if(the weshare ~~license~~price ~~our~~at ~~products to future collaborators, from~~ the ~~receipt~~time of ~~license~~issuance) ~~fees~~to ~~and~~consultants ~~royalties~~who ~~from~~are ~~licensed~~also ~~products~~accredited investors.

~~Management estimates that our research and development expenses for the next 12 months will be approximately $3~~1.0 million, primarily for research and pilot studies. We also estimate that other expenses, including personnel, general and administrative and miscellaneous expenses could be as much as $2.0 million during the same time period. Because we currently have no revenues, most likely the only source of funding these expenses will be through the private sale of our securities, either equity or debt. We are currently exploring possible funding sources, but we have not entered into any arrangements or agreements for funding as of this time. If we are unable to raise the necessary funding, our research and development plans will be delayed indefinitely. There can be no assurance that we will be able to raise the funds necessary to carry out our business plan on terms favorable to the company, or at all.

~~Forward-Looking~~Commitments and ~~Cautionary~~Contingencies ~~Statements~~

~~Statements contained in this report which are not historical facts, may be considered "forward-looking statements," which term is defined by the Private Securities~~ Litigation Reform Act of 1995. Any "safe harbor under this Act does not apply to a "penny stock" issuer, which definition would include the company. Forward-looking statements are based on current expectations and the current economic environment. We caution readers that such forward-looking statements are not guarantees of future performance. Unknown risks and uncertainties as well as other uncontrollable or unknown factors could cause actual results to materially differ from the results, performance or expectations expressed or implied by such forward-looking statements.

14The ~~Table~~Company may, from time to time, become involved in various lawsuits and legal proceedings, which arise in the ordinary course of ~~Contents~~business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company is currently not aware of any such legal proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its

~~Item 3~~2. ~~Quantitative and Qualitative Disclosures About Market Risk.~~

~~This~~Subsequent ~~item~~Events ~~is not required for a smaller reporting company.~~

~~Item~~We 4.have ~~Controls~~evaluated subsequent events through the date of issuance of the unaudited consolidated financial statements, and ~~Procedures~~below are the material recognizable subsequent events.

Evaluation of Disclosure Controls and Procedures. Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures.·

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. In ~~designing~~April ~~and evaluating the disclosure controls and procedures~~2017, ~~management recognizes that there are inherent limitations to~~ the ~~effectiveness~~Company ofissued ~~any system of disclosure controls and procedures~~100,000 ~~including~~shares ~~the possibility~~ of ~~human~~common ~~error~~stock ~~and~~at the ~~circumvention~~market orprice overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. Based on the ~~evaluation~~date ~~described above, our management, including our chief executive officer and chief financial officer, concluded that, as~~ of ~~September 30, 2016, our disclosure controls and procedures were not effective due to a lack of adequate segregation of duties and the absence of an audit committee~~issue.

Changes in Internal Control Over Financial Reporting. Management has evaluated whether any change in our internal control over financial reporting occurred during the quarter ended September 30, 2016. Based on its evaluation, management, including the chief executive officer and chief financial officer, has concluded that there has been no change in our internal control over financial reporting during the quarter ended September 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.·

15In ~~Table~~May 2017, the Company issued 5,250,000 shares of ~~Contents~~common stock at the market price on the date of issue.

~~PART II — OTHER INFORMATION~~·

~~Item~~In 1June 2017, the Company issued 500,000,000 shares of common stock to its CEO and its President (250,000,000 each) at a price of $0.0001 ~~Legal~~per ~~Proceedings~~common shares.

There are no material pending legal proceedings to which we are a party or to which any of our property is subject and, to the best of our knowledge, no such actions against us are contemplated or threatened.·

~~Item~~ In 1AJune 2017, the Company issued 87,333,333 shares of common stock to its consultants in exchange for their services. The ~~Risk~~shares ~~Factors~~were issued at the market price on the date of issuance.

~~This item is not required for a smaller reporting company.~~·

~~Item~~In 2.October ~~Unregistered~~2017, ~~Sales~~the Company issued 13,000,000 shares of ~~Equity~~common ~~Securities~~stock ~~and~~to ~~Use~~consultants in exchange for their services. The shares were issued at the market price on the date of ~~Proceeds~~issuance.

On February 1, 2016, we issued 23,400,000 shares of common stock to consultants for services rendered at the price of $0.0322 per share. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering. ·

~~Item~~In 3January 2018, the Company issued 5,000,000 shares of common stock to consultants in exchange for their services. The ~~Defaults~~shares ~~Upon~~were ~~Senior~~issued ~~Securities~~at the market price on the date of issuance.

~~This~~· In ~~Item~~July is2018, ~~not~~the ~~applicable~~Company issued 37,500,000 shares of common stock to consultants in exchange for their services.

~~Item~~· In 4July 2017, the Company issued 600,000 shares of preferred stock to consultants in exchange for their services. The ~~Mine~~shares ~~Safety~~were ~~Disclosures~~issued at $0.01 per share, and convert 1:1 into common shares.

~~This Item is not applicable.~~F-9

Item 52. ~~Other Information~~

~~This~~Management’s ~~Item~~Discussion isand ~~not~~Analysis ~~applicable.~~of Financial Condition and Results of Operations

~~16 Table~~Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of ~~Contents~~ future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

~~Item~~Overview 6.& ~~Exhibits~~ General History

Exhibit 31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Organization

17Eastgate ~~Table~~Biotech Corp. (The Company) was organized on September 8, 1999, under the laws of ~~Contents~~the State of

~~SIGNATURES~~Nevada, and is traded on the OTCPink exchange.

~~Pursuant~~Nature ~~to the requirements~~ of ~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Business

	EASTGATE BIOTECH CORP.
Date: March 15, 2017	By:	/s/ Anna Gluskin
		Anna Gluskin
		Chief Executive Officer
		(Principal Executive Officer)

The Company is engaged in the research and development of drug delivery innovations, development of improved and novel formulations, and forms of alternative dosage delivery of existing biologically active molecules.

Date: March 15, 2017	By:	/s/ Rose Perri
		Rose Perri
		President and Treasurer
		(Principal Financial and Accounting Officer)

We are primarily engaged in the development of novel formulations of natural compounds and pharmaceutical products. We intend to accomplish this by developing our proprietary self-emulsifying drug delivery systems, predominantly forming Nano-emulsions. Although we have not finalized any pharmaceuticals products and are in the early stages of research, our goal is to be able to develop patentable and Trade Secret formulations of pharmaceutical, nutraceutical dietary supplements and consumer health products. We recently started marketing and distribution and have limited sales for some of our nutraceuticals products.

18Some of our proposed products under development are based on existing natural compounds. Many of these proposed products are made of essential oils and plant extracts. Our proposed products comprise excipients listed in the FDA “Inactive Ingredients Guide” that we believe are safe and approved for human consumption. Additionally, we believe that these proposed products can be manufactured using common equipment. We anticipate that we will be able to apply self-emulsifying technologies for development of a variety of pharmaceuticals and natural products for different applications.

Results of Operations for the three months ended March 31, 2017 and 2016.

Operating Revenues

In the three-month period ended March 31, 2017 and 2016, we generated $0 and $0, respectively, in revenue from the sales of drug delivery systems, natural compounds, and pharmaceutical products.

Cost of Goods Sold

In the three-month periods ended March 31, 2017 and 2016, we incurred $0 and $0, respectively, as cost of goods sold.

Gross profit (loss)

The Company did not have any gross profit (loss) in the three-month periods ended March 31, 2017 and 2016.

Operating Expenses

Our operating expenses for the three-month periods ended March 31, 2017 and 2016 are outlined in the table below:


	Three Months Ended
	March 31,
	2017	2016
Professional fees	$ 42,667	$ 2,636
Research & development	175,990	138,641
General and administrative	635,941	1,032,220
Marketing & selling	60,090	70,281
Total	$ 914,688	$ 1,243,778

Operating expenses for the three-months ended March 31, 2017 was $914,688 and $1,243,778, respectively. The decrease in operating expense during the three-months ended March 31, 2017 versus 2016 is primarily attributed to a decrease in general and administrative costs.

Other Expenses

In addition to operating expenses, we incurred interest expenses of $37,424 and $35,336 during the three-months ended March 31, 2017, and 2016, respectively. The increase in interest expense during the period ended March 31, 2017 is primarily attributable to the fact that the debt was added incrementally throughout 2017. In addition, for the three-month period ended March 31, 2016, the Company recorded a loss from impairment of assets with no similar discontinued operations of $184,402.

Net Loss

We incurred a net loss of $952,111 and $1,463,516 for the three-months ended March 31, 2017 and 2016, respectively.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

To date we have financed our operations through sales of common stock and the issuance of debt.

The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing and generating profitable operations from the Company’s future operations. However, there can be no assurance that these arrangements will be sufficient to fund its ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

Working Capital


			Percentage
	March 31,	December 31,	Increase
	2017	2016	(Decrease)
Current Assets	$ 9,348	$ -	-%
Current Liabilities	$ 4,894,110	$ 4,578,042	6.9%
Working Capital Deficit	$ (4,884,762)	$ (4,578,042)	6.7%

At March 31, 2017, our cash balance was $9,348 compared to $0 at December 31, 2016. The increase in cash is attributed to proceeds of $71,563 in notes payable to a related party, and proceeds of $70,403 from other notes, all of which were used to pay operating expenses.

At March 31, 2017, we had total current liabilities of $4,894,110, compared with total current liabilities of $4,578,042 at December 31, 2016. The increase in total liabilities is attributed to an increase in notes payable to related parties, deferred sales, and increases in accounts payable and accrued liabilities of $148,181 and accrued interest of $18,000.

At March 31, 2017, we had a working capital deficit of $4,884,762 compared with a working capital deficit of $4,578,042 at December 31, 2016. The increase in working capital deficit is primarily due to an increase in related party loans of $71,563 and increases in accounts payable and accrued expenses which were offset by cash obtained from proceeds of common stock sales.

Cash Flows


	For the Three Months Ended		Percentage
	March 31,	March 31,	Increase
	2017	2016	(Decrease)
Cash Used in Operating Activities	$ (121,479)	$ (103,503)	(17.4) %
Cash Used in Investing Activities	-	-	-%
Cash Provided by Financing Activities	141,966	92,104	54.1%
Net Increase (decrease) in Cash	$ 20,487	$ (11,399)	279.7%

Cash flow from Operating Activities

During the three months ended March 31, 2017, we used $121,479 of cash in operating activities compared to the use of $103,503 of cash for operating activities during the three months ended March 31, 2016. The increase in the use of cash for operating activities was mainly attributed to positive cash flow adjustments of 830,632 to our 2017 period net loss of $952,111, which were less than the positive cash flow adjustments of $1,360,013 to our 2016 period loss of $1,463,516.

Cash flow from Investing Activities

During the three months ended March 31, 2017 and 2016, we used $0 in investing activities.

Cash flow from Financing Activities

During the three months ended March 31, 2017 and 2016, we received net proceeds of $141,966 and $92,104, respectively from financing activities. The increase in proceeds from financing activities is mainly attributed to $70,403 in proceeds from notes payable which were not present in the 2016 period, offset by proceeds from notes payable related parties of $71,563 in the 2017 period compared to $94,077 in the 2016 period.

Going Concern

These accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of March 31, 2017, the Company had an accumulated deficit of $15,583,102 and negative working capital of $4,884,762. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing and generating profitable operations from the Company’s future operations. However, there can be no assurance that these arrangements will be sufficient to fund its ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These accompanying unaudited consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

Future Financings

We intend to continue to rely on loans from related parties and the private sales of our shares of common stock in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund our operations and other activities.

Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Our significant accounting policies are more fully described in Note 5 to our unaudited consolidated financial statements included in this Quarterly Report.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.

Off-Balance Sheet Arrangements

We had no off-balance sheet arrangements as of March 31, 2017 and December 31, 2016.

Inflation

We do not believe that inflation has had a material effect on our Company’s results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not Applicable.

Item 4. Controls and Procedures.

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2017. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

Changes in Internal Control Over Financial Reporting

During the quarter ended March 31, 2017, management evaluated whether any change in our internal control over financial reporting during the period then ended had taken place. Based on its evaluation, management, including the chief executive officer and chief financial officer, has concluded that there has been no change in our internal control over financial reporting during the quarter ended March 31, 2017 that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.

PART II-OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 1A. Risk Factors.

Not Applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In January 2017, the Company issued 1,000,000 shares of common stock at an average price of $0.0318 per share (the share price at the time of issuance) to consultants who are also accredited investors.

In February 2017, the Company issued 8,100,000 shares of common stock at an average price of $0.0399 per share (the share price at the time of issuance) to consultants who are also accredited investors.

In March 2017, the Company issued 3,000,000 shares of common stock at an average price of $0.04 per share (the share price at the time of issuance) to consultants who are also accredited investors.

In March 2017, the Company issued 500,000 shares of common stock at an average price of $0.043 per share (the share price at the time of issuance) to consultants who are also accredited investors.

In April 2017, the Company issued 100,000 shares of common stock at the market price on the date of issue.

In May 2017, the Company issued 5,250,000 shares of common stock at the market price on the date of issue.

In June 2017, the Company issued 500,000,000 shares of common stock to its CEO and its President (250,000,000 shares each) at a price of $0.0001 per common shares.

In June 2017, the Company issued 87,333,333 shares of common stock to its consultants in exchange for their services. The shares were issued at the market price on the date of issuance.

In October 2017, the Company issued 13,000,000 shares of common stock to consultants in exchange for their services. The shares were issued at the market price on the date of issuance.

In January 2018, the Company issued 5,000,000 shares of common stock to consultants in exchange for their services. The shares were issued at the market price on the date of issuance.

In July 2018, the Company issued 37,500,000 shares of common stock to consultants in exchange for their services. The shares were issued at the market price on the date of issuance.

In July 2017, the Company issued 600,000 shares of preferred stock to consultants in exchange for their services. The shares were issued at $0.01 per share, and convert 1:1 into common shares.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Subsequent Events

Filing Compare · EASTGATE BIOTECH CORP